Agile Therapeutics Inc (STU:0AL)
€ 9.83 0 (0%) Market Cap: 7.41 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Q2 2023 Agile Therapeutics Inc Earnings Call Transcript

Aug 09, 2023 / 12:30PM GMT
Operator

Good morning, and welcome to the Agile Therapeutics Second Quarter 2023 Financial Results Conference Call. Please note today's event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations.

Matthew Riley
Agile Therapeutics, Inc. - Head of IR & Corporate Communications

Hello, everyone, and welcome to today's conference call to discuss our second quarter 2023 financial results and corporate update. Before we start, let me remind you that today's call will include forward-looking statements based on our current expectations, including statements concerning our financial outlook and financing prospects for the future.

Our outlook for the second half of 2023, management's expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla and our operating expenses. Our business strategy, our partnerships with the Afaxys and Syneos and their ability to promote growth, our relationship with Nurx and its ability to make Twirla broadly

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot